Dexcom Reports Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
DexCom (DXCM) PT Raised to $86 at Bernstein SocGen Group
October 25, 2024 6:25 AM EDTBernstein SocGen Group analyst Lee Hambright raised the price target on DexCom (NASDAQ: DXCM) to $86.00 (from $82.00) while maintaining a Market Perform rating.
The analyst comments "In-line quarter. Revenue grew 3% organic, landing at the high-end of the reduced guidance range that DXCM set on the Q2 call (1% to 3%). U.S. sales declined -2% organic,... More
BTIG Reiterates Buy Rating on DexCom (DXCM)
October 25, 2024 5:23 AM EDTBTIG analyst Marie Thibault reiterated a Buy rating and $120.00 price target on DexCom (NASDAQ: DXCM).
The analyst comments "Dexcom reported $994.2M in Q3 revenue (+2% y/y rep., +3% y/y org.), $4M above the consensus estimate of $990M. Q3 adj. EPS was $0.45, two cents above consensus. DXCM missed Visible Alpha consensus' U.S. sales expectation by $19M, reporting $701.9M (-2% y/y) and beat by $22M on OUS sales of $292.3M (+12% y/y rep.). Despite the light U.S. result, management commentary was upbeat, highlighting a record level of new patient starts, progress and momentum on... More
